Display options
Cite
Zhang YK, Dai C, Yuan CG, et al. Establishment and characterization of arsenic trioxide resistant KB/ATO cells. Acta Pharm Sin B. 2017;7(5):564-570doi: 10.1016/j.apsb.2017.04.001.
Zhang, Y. K., Dai, C., Yuan, C. G., Wu, H. C., Xiao, Z., Lei, Z. N., Yang, D. H., Le, X. C., Fu, L., & Chen, Z. S. (2017). Establishment and characterization of arsenic trioxide resistant KB/ATO cells. Acta pharmaceutica Sinica. B, 7(5), 564-570. https://doi.org/10.1016/j.apsb.2017.04.001
Zhang, Yun-Kai, et al. "Establishment and characterization of arsenic trioxide resistant KB/ATO cells." Acta pharmaceutica Sinica. B vol. 7,5 (2017): 564-570. doi: https://doi.org/10.1016/j.apsb.2017.04.001
Zhang YK, Dai C, Yuan CG, Wu HC, Xiao Z, Lei ZN, Yang DH, Le XC, Fu L, Chen ZS. Establishment and characterization of arsenic trioxide resistant KB/ATO cells. Acta Pharm Sin B. 2017 Sep;7(5):564-570. doi: 10.1016/j.apsb.2017.04.001. Epub 2017 Apr 28. PMID: 28924550; PMCID: PMC5595296.
Copy Download .nbib Format: NLM
Share it on

Acta Pharm Sin B. 2017 Sep;7(5):564-570. doi: 10.1016/j.apsb.2017.04.001. Epub 2017 Apr 28.

Establishment and characterization of arsenic trioxide resistant KB/ATO cells.

Acta pharmaceutica Sinica. B

Yun-Kai Zhang, Chunling Dai, Chun-Gang Yuan, Hsiang-Chun Wu, Zhijie Xiao, Zi-Ning Lei, Dong-Hua Yang, X Chris Le, Liwu Fu, Zhe-Sheng Chen

Affiliations

  1. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John?s University, Queens, NY 11439, USA.
  2. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  3. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton T6G 2G3, Alberta, Canada.

PMID: 28924550 PMCID: PMC5595296 DOI: 10.1016/j.apsb.2017.04.001

Abstract

Arsenic trioxide (ATO) is used as a chemotherapeutic agent for the treatment of acute promyelocytic leukemia. However, increasing drug resistance is reducing its efficacy. Therefore, a better understanding of ATO resistance mechanism is required. In this study, we established an ATO-resistant human epidermoid carcinoma cell line, KB/ATO, from its parental KB-3-1 cells. In addition to ATO, KB/ATO cells also exhibited cross-resistance to other anticancer drugs such as cisplatin, antimony potassium tartrate, and 6-mercaptopurine. The arsenic accumulation in KB/ATO cells was significantly lower than that in KB-3-1 cells. Further analysis indicated that neither application of P-glycoprotein inhibitor, breast cancer resistant protein (BCRP) inhibitor, or multidrug resistance protein 1 (MRP1) inhibitor could eliminate ATO resistance. We found that the expression level of ABCB6 was increased in KB/ATO cells. In conclusion, ABCB6 could be an important factor for ATO resistance in KB/ATO cells. The ABCB6 level may serve as a predictive biomarker for the effectiveness of ATO therapy.

Keywords: ABCB6; Arsenic trioxide; Biomarker; KB-3-1 cells; KB/ATO cells; Multidrug resistance

References

  1. Sci Prog. 1999;82 ( Pt 1):69-88 - PubMed
  2. Cancer Chemother Pharmacol. 2010 Sep;66(4):681-9 - PubMed
  3. Oncotarget. 2015 Sep 15;6(27):24277-90 - PubMed
  4. J Hist Med Allied Sci. 1992 Apr;47(2):186-209 - PubMed
  5. Sci Rep. 2016 May 09;6:25694 - PubMed
  6. AAPS J. 2015 Jul;17(4):802-12 - PubMed
  7. Leukemia. 2001 Aug;15(8):1176-84 - PubMed
  8. Oncogene. 2001 Oct 29;20(49):7257-65 - PubMed
  9. Nature. 2006 Oct 5;443(7111):586-9 - PubMed
  10. Cancer Lett. 2014 Jun 1;347(2):159-66 - PubMed
  11. Toxicol Sci. 2011 Apr;120(2):519-28 - PubMed
  12. Mol Pharmacol. 2014 Aug;86(2):168-79 - PubMed
  13. Curr Pharm Biotechnol. 2011 Apr;12(4):570-94 - PubMed
  14. Blood. 1997 May 1;89(9):3487-8 - PubMed
  15. Lancet Oncol. 2000 Oct;1:101-6 - PubMed
  16. Clin Chim Acta. 1977 Oct 15;80(2):299-303 - PubMed
  17. Metallomics. 2015 Jan;7(1):39-55 - PubMed
  18. Oncol Rep. 2007 Sep;18(3):721-7 - PubMed
  19. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 - PubMed
  20. Int J Hematol. 2013 Jun;97(6):717-25 - PubMed
  21. Biochemistry. 2007 Aug 21;46(33):9443-52 - PubMed
  22. Res Microbiol. 2001 Apr-May;152(3-4):331-40 - PubMed
  23. J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 - PubMed

Publication Types

Grant support